



Europäisches
Patentamt

European
Patent Office

PGI/EP 03/10473 #2

Rec'd PCT/PTO 22 MAR 2005

Office européen
des brevets

REC'D 18 NOV 2003

WIPO PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02021098.5

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

BEST AVAILABLE COPY



Anmeldung Nr:
Application no.: 02021098.5
Demande no:

Anmeldetag:
Date of filing: 23.09.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Roche Vitamins AG

4070 Basel
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Enone reductase gene and microbial production of levodione

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C12N9/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

Enone Reductase Gene and Microbial Production of Levodione

The present invention relates to a DNA encoding an enone reductase, an expression vector comprising the DNA, a microorganism into which the DNA has been introduced, and a method for producing (6R)-2,2,6-trimethyl-1,4-cyclohexanedione (hereinafter referred to as levodione) from 2,6,6-trimethyl-2-cyclohexene-1,4-dione (hereinafter referred to as ketoisophorone) using the microorganism.

Levodione is a useful intermediate in the synthesis of optically active carotenoids such as zeaxanthin. A microbiological process of producing levodione from ketoisophorone is known (US 4,156,100). Enone reductase that acts on ketoisophorone to produce levodione, which was isolated from *Candida kefyr* was described in (European Patent Application No. 02003967.3 filed on Feb. 22, 2002). This enzyme is characterized by the following physico-chemical properties:

- (a) molecular mass: $61,300 \pm 5,000$ Da
(Estimated using gel filtration. Consisting of one subunit.)
- (b) Co-factor: NADPH and NADH
- (c) Substrate specificity: active on α,β -unsaturated ketons
- (d) Optimum temperature: 55-60°C at pH 7.4
- (e) Optimum pH: pH 4.5-8.5

As used herein, the term "enone reductase" encompasses proteins catalyzing the enzymatic reduction of carbonyl activated double bonds according to the Enzyme Nomenclature provided by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB). It also relates to proteins having the above mentioned activities of an enone reductase, which proteins preferably catalyse the conversion of ketoisophorone into levodione. The gene for an enone reductase involved in the biosynthesis

HEI/sk 23.09.2002

of levodione would be very useful for improvement of levodione productivity by a micro-organism.

The present invention provides to an isolated DNA sequence encoding enone reductase.

5 The isolated DNA sequence may be more specifically characterized in that (a) it codes for the enzyme having the amino acid sequence described in SEQ ID NO:2, or (b) it codes for a variant of the enzyme selected from (i) an allelic variant, and (ii) an enzyme having one or more amino acid addition, insertion, deletion and/or substitution and having the stated enzyme activity.

10 More particularly, the present invention provides an isolated DNA sequence derived from a gene of *Candida kefyr* (*Candida macedoniensis*) IFO 0960 and is selected from (i) the DNA sequence represented in SEQ ID NO:1, (ii) an isocoding or an allelic variant of the DNA sequence represented in SEQ ID NO:1, (iii) a derivative of the DNA sequence represented in SEQ ID NO:1, with addition, insertion, deletion and/or substitution of one or more nucleotide(s) and coding for a polypeptide having the enzyme activity, (iv) the DNA
15 sequence which hybridizes to the complement of the nucleotide sequence of (i) or (ii) under stringent hybridizing conditions and coding for a polypeptide having the enzyme activity, and (v) the DNA sequence which is at least 80% identical to the nucleotide sequence of (i) and coding for a polypeptide having the enzyme activity.

20 The strain *Candida kefyr* (*Candida macedoniensis*) IFO 0960 is publicly available from the Institute for Fermentation Osaka (IFO), 17-85 Jusohonmachi 2-chome, Yodogawa-ku, Osaka, 532-8686, Japan.

Instructions for identifying DNA sequences by means of hybridization are well-known to a person skilled in the art. The hybridization may take place under stringent conditions wherein only hybrids in which the probe and target sequence, i.e. the polynucleotides
25 treated with the probe and are at least 70% identical, are formed. It is known that the stringency of the hybridization, including the washing steps, is influenced or determined by varying the buffer composition, the temperature and the salt concentration. The hybridization reaction is preferably carried out under a relatively low stringency compared with the washing steps.

30 A 5 x SSC buffer at a temperature of approx. 50-68°C, for example, can be employed for the hybridization reaction. Probes can also hybridize here with polynucleotides that are less than 70% identical to the sequence of the probe. Such hybrids are less stable and are removed by washing under stringent conditions. This can be achieved, for example, by

lowering the salt concentration to 2 x SSC and subsequently 0.5 x SSC at a temperature of approx. 50-68°C being established. It is optionally possible to lower the salt concentration to 0.1 x SSC. Polynucleotide fragment, for example, at least 70% or at least 80%, or at least 90% to 95% identical to the sequence of the probe employed can be isolated by increasing
5 the hybridization temperature stepwise in steps of approx. 1-2°C.

"Stringent conditions" in the context of this invention mean hybridization in a buffer, for example, consisting of 5 x SSC, 0.1% (w/v) N-lauroylsarcosine, 0.02% (w/v) SDS, 1% blocking reagent (Roche Diagnostics, Cat. No. 1096 176) at 50°C overnight and two times of washing with 2 x SSC, 0.1% (w/v) SDS for 5 min. at room temperature and following
10 two times of washing with 0.1 x SSC, 0.1% (w/v) SDS for 15 min. at 68°C in the washing step of hybridization.

The DNA sequence may be cloned from a strain of *C. kefir* (*C. macedoniensis*) IFO 0960, or another or related organism and thus, for example, may be an allelic or species variant of an enone reductase encoding region of the DNA sequence. Also included within the
15 scope of the present invention is a derivative of the DNA sequence with addition, insertion, deletion and/or substitution of different nucleotides resulting in a polypeptide that encodes the same or a functionally equivalent levodione reductase. The encoded protein may also contain addition, deletion, insertion and/or substitution of amino acid residues, which produce a silent change and result in a functionally equivalent enone
20 reductase.

The DNA of the present invention also means a genomic DNA that contains regulatory sequences such as a promoter and a terminator, which are involved in the expression of the gene of interest, and also a cDNA that contains only open reading frame flanked between the short fragments in its 5'- and 3'- untranslated region.

25 The enone reductase gene, the recombinant expression vector, and the recombinant organisms utilized in the present invention may be obtained by the following steps:

- Isolating chromosomal DNA from a microorganism that can provide enone reductase of the present invention and constructing the gene library with the chromosomal DNA.
- Cloning an enone reductase gene from the chromosomal DNA by colony- or plaque-
30 hybridization, PCR cloning, Southern-blot hybridization and so on.
- Determining nucleotide sequence of the enone reductase gene obtained as above by usual methods and constructing recombinant expression vectors which contain and express the enone reductase gene efficiently.

- Constructing recombinant organisms carrying the enone reductase gene on recombinant expression vectors or on chromosomes by transformation, transduction, transconjugation or electroporation.

5 The techniques used to isolate or clone a DNA encoding enone reductase of the present invention are known in the art and include isolation from genomic DNA. The cloning of the DNA sequence of the present invention from such genomic DNA can be effected by using the degenerate polymerase chain reaction (hereinafter referred to as PCR).

10 On the basis of information on the partial amino acid sequence oligonucleotides as primers for PCR may be synthesized. The primers used for cloning of the enone reductase gene by PCR may be based on the amino acid sequence of the peptide fragments of the purified enone reductase from the genera including, but not limited to, *Candida* and *Zygosaccharomyces*, and in the most preferred embodiment, from *C. kefyr* (*C. macedonien-*
15 *sis*) IFO 0960. A DNA fragment (a partial DNA sequence) of enone reductase is generated by PCR amplification with the primers and the template of, e.g., *C. kefyr* chromosomal DNA. The amplified DNA fragment can be used as the probe to clone a genomic fragment coding for the whole enone reductase. An entire gene containing its coding region as well as its regulation region such as a promoter or terminator can be cloned from a chromosome, for example, by inverse PCR method using primers based on part of sequence of the
20 obtained DNA fragment after it was sequenced, or screening of genomic library which is constructed in phage vector or plasmid vector in an appropriate host, by using a partial DNA fragment obtained by PCR as described above as a probe after it was labeled.

Generally, *E. coli* as a host strain and *E. coli* vector, a phage vector such as λ phage vector, a plasmid vector, or a yeast vector is often used in the construction of library and a following genetic manipulation such as sequencing, restriction digestion, ligation and so on. After
25 the isolation of all necessary parts of the entire gene containing its coding region as well as its regulation region, obtained fragments were subcloned into an appropriate plasmid vector, which can be conveniently used for sequencing and construction of the entire gene of the enone reductase. In this invention, the insert fragments were subcloned into pUC18 vector. Nucleotide sequence can be determined by a well-known method such as dideoxy
30 chain-termination method.

The isolated DNA sequence of the present invention may be used to identify and clone DNA encoding a polypeptide having enone reductase activity from other strains of different genera or species according to methods well known in the art.


The present invention also relates to a recombinant DNA, preferably a vector and/or plasmid comprising a sequence coding for enone reductase. The recombinant DNA vector and/or plasmid may comprise the regulatory regions such as promoters and terminators as well as open reading frames of a enone reductase gene. Methods which are well known to those skilled in the art may be used to construct expression vectors containing a nucleotide sequence encoding enone reductase and appropriate transcriptional and translational regulatory elements including all components which are necessary or advantageous for expression of the coding sequence of the nucleotide sequence. Specific initiation and termination signals may also be used to achieve more efficient translation of sequences encoding enone reductase. An isolated DNA sequence encoding enone reductase may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the nucleotide sequence encoding enone reductase prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleotide sequences utilizing cloning methods are well known in the art. A variety of expression vector/host systems may be utilized to contain and express sequences encoding enone reductase.

The present invention also provides the use of the recombinant DNA to transform a host organism. A convenient form of the recombinant DNA may be a vector. The host organism transformed with the recombinant DNA may be useful in the production of a polypeptide of enone reductase and also useful in the improvement of the production process of levodione. Thus, the present invention also provides such a transformed host cell (recombinant microorganism) and a polypeptide encoded by the recombinant DNA.

The present invention also provides a process for the production of the polypeptide encoded by the recombinant DNA, which comprises culturing the transformed host cell under the conditions suitable for the expression of the enzyme and recovery of the polypeptide from the cell culture. Cultivation of the recombinant microorganism can be carried out aerobically or anaerobically at pH values from 4.0 to 9.0, at a temperature in the range of from 10 to 60°C, for 15 minutes to 72 hours, preferably, at pH values from 5.0 to 8.0, at a temperature in the range of from 20 to 40°C for 30 minutes to 48 hours. The enone reductase produced by the recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. The enone reductase may then be isolated from the culture medium or the recombinant cell by conventional procedures.

The present invention further provides a process for the production of levodione, which comprises contacting ketoisophorone with the polypeptide enone reductase.

The enone reductase of the present invention catalyzes the reduction of ketoisophorone to levodione in the presence of a co-factor, NADH or NADPH, according to the following formula:



- 5 The reaction can be conducted in a solvent such as Tris-HCl buffer and phosphate buffer.

Preferable conditions for the reaction are pH values from 4.5 to 8.5, more preferably from 5.0 to 8.0, a temperature range of from 10 to 60°C, more preferably from 20 to 60°C, for a period of 5 minutes to 72 hours, more preferably for 15 minutes to 48 hours.

- 10 The present invention also provides a method for the biological production of levodione, which comprises contacting ketoisophorone with a recombinant microorganism as described above, including cultivation of the recombinant microorganism in the presence of ketoisophorone as a substrate, under conditions suitable for the production of levodione, and isolating the resulting levodione from the reaction mixture.

- 15 Either a growing or a resting cell culture or immobilized cells or a cell-free extract, or the like, of the recombinant microorganism may be used for the production of levodione.

- The growing cell culture can be obtained by culturing the recombinant microorganism in a nutrient medium containing saccharides such as glucose or sucrose, alcohols, such as ethanol or glycerol, fatty acids, such as oleic acid and stearic acid or esters thereof, or oils, such as rapeseed oil or soybean oil, as carbon sources; ammonium sulfate, sodium nitrate, 20 peptone, amino acids, corn steep liquor, bran, yeast extract and so on, as nitrogen sources; magnesium sulfate, sodium chloride, calcium carbonate, potassium monohydrogen phosphate, potassium dihydrogen phosphate, and so on, as inorganic salt sources; and malt extract, meat extract, and so on, as other nutrient sources. Cultivation of the recombinant microorganism can be carried out aerobically or anaerobically at pH values from 4.0 to 25 9.0, at a temperature in the range of from 10 to 60°C for 15 minutes to 72 hours, preferably, at pH values from 5.0 to 8.0, at a temperature in the range of from 20 to 40°C for 30 minutes to 48 hours. Appropriate mixing of the culture during the cultivation will be preferable for the cell growth or the reaction.

- 30 Using the growing cell culture thus obtained, a resting cell culture or immobilized cells or a cell-free extract may be prepared by any means generally known in the art.

Preferable conditions for the production of levodione are pH values from 4.0 to 9.0 and a temperature range of from 10 to 60°C for a period of 15 minutes to 72 hours.

More preferable conditions for the production of levodione are pH values from 5.0 to 8.0 and a temperature range of from 20 to 60°C for a period of 30 minutes to 48 hours.

- 5 The concentration of ketoisophorone in a reaction mixture can vary depending on other reaction conditions, but, in general, is between 0.1 g/l and 300 g/l, preferably between 1 g/l and 30 g/l.

Levodione produced enzymatically or biologically in a reaction mixture as described above may be extracted by an organic solvent such as ethyl acetate, n-hexane, toluene, or n-butyl.

- 10 The extract may be analyzed by known method such as gas chromatography, high performance liquid chromatography, thin layer chromatography or paper chromatography, or the like. In case of gas chromatography, the following condition can be applied as an example: Column: ULBON HR-20M (Shinwa, Japan) 0.25 mm x 30m; Column temperature: 160°C (constant); Injector temperature: 250°C; Carrier gas: He (ca. 1ml/min)

- 15 After the reaction, levodione in the reaction mixture may be recovered, for example, by extraction with a water-immiscible organic solvent, which readily solubilizes levodione, such as ethyl acetate, n-hexane, toluene, or n-butyl acetate. Further purification of levodione can be effected by concentrating the extract to directly crystallize levodione or by the combination of various kinds of chromatography, for example, thin layer chromatography, 20 adsorption chromatography, ion-exchange chromatography, gel filtration chromatography or high performance liquid chromatography.

The following Examples further illustrate the present invention.

Example 1: Partial amino acid sequence of enone reductase of *C. kefir* (*C. macedoniensis*) IFO 0960

- 25 The freeze-dried purified enone reductase (as described in European Patent Application No. 02003967.3 filed on Feb. 22, 2002) of *C. kefir* was digested with lysyl endopeptidase, and the resulting digest was separated by the Smart system, i.e., one nmol of the purified enzyme was dissolved in 25 µl of 50mM Tris-HCl buffer (pH 8.6) containing 8 M urea, and incubated at 37°C for 1 hour. After this, 25 µl of 50 mM Tris-HCl buffer (pH 8.6) 30 were added to make the concentration of urea 4 M. Then, 0.5 µl of 12 nmol/ml lysyl endopeptidase (Wako, Japan, 0.006 nmol, E/S=1/167) was added, and incubated at 30°C

for 6 hours. The resulting peptides were separated by the Smart system using the following conditions: Column: μ RPC C2/C18 SC2.1/10 (Amersham Bioscience / Buckinghamshire, England); Flow rate: 100 μ l/min; Liquid A: 0.1 % TFA; Liquid B: 0.1 % TFA + 80 % CH_3CN ; Gradient: 100 % A (0-15 min); 100 % A \longrightarrow 100 % B (15-75 min); Column temperature: Room temperature; Detection: 214 nm, 280 nm.

The peptides (K-15, K-25.1, K-6.1, K-6.2, K30, K13.2, K-1.1, K-1.2, K-33, K-25.2, K-20, K-17, K-22, K-4.1, K-13.1, and K-9) were isolated, and the amino acid sequences of these peptides were analyzed with a protein sequencer, i.e. by automated Edman degradation with a model 491HT pulsed liquid protein sequencer (Applied Biosystems, Foster City, California) to be Peptide K-15: SEQ ID NO: 3; Peptide K-25.1: SEQ ID NO: 4; Peptide K-6.1: SEQ ID NO: 5; Peptide K-6.2: SEQ ID NO: 6; Peptide K-30: SEQ ID NO: 7; Peptide K-13.2: SEQ ID NO: 8; Peptide K-1.1: SEQ ID NO: 9; Peptide K-1.2: SEQ ID NO: 10; Peptide K-33: SEQ ID NO: 11; Peptide K-25.2: SEQ ID NO: 12; Peptide K-20: SEQ ID NO: 13; Peptide K-17: SEQ ID NO: 14; Peptide K-22: SEQ ID NO: 15; Peptide K-4.1: SEQ ID NO: 16; Peptide K-13.1: SEQ ID NO: 17; and Peptide K-9: SEQ ID NO: 18.

The partial amino acid sequence obtained was compared with the sequences of proteins stored in the SWISS-PROT (release 37.0+/06-14, June 99), PIR (release 60.0, March 99), and PRF (release 99-05, May 99) protein databases. Sequence alignment was performed by using Blast (J. Mol. Biol., 215, 403-410, 1990) and Fasta (Proc. Natl. Acad. Sci. USA, 85, 2444-2448, 1988) programs. As a result, high homology with known Old Yellow Enzymes was found.

Example 2: Preparation of chromosomal DNA of *C. kefir* (*C. macedoniensis*) IFO 0960

The cells of *C. kefir* (*C. macedoniensis*) IFO 0960 were cultivated in 200 ml medium. Cells were collected by centrifugation and suspended in 10 ml TES buffer. 3 ml of 0.5 M EDTA, 0.5 ml of Zymolyase solution, and 0.5 ml of Proteinase K solution were added to the cell suspension. After incubation at 37°C for 0.5 hour with gently mixing, 2 ml of 10 % SDS was added and mixed. After addition of H_2O to make the volume 20 ml, 10 ml of TE-saturated phenol and 10 ml of chloroform were added and mixed. The upper layer was collected after centrifugation, the same volume of phenol/chloroform was added and mixed. After centrifugation, upper layer was collected and added with 0.1 x volume of 3M sodium acetate and 2.5 x volume of ethanol. Using a winding glass rod, DNA precipitate was collected, rinsed with 70 %, 80 %, and 90 % ethanol, dried and resuspended in 5 ml of TE buffer containing 10 μ l of 5 mg/ml RNase A. DNA was completely dissolved by gently

mixing at 4°C over night. 10 µl of 5 mg/ml RNase A were added again, and the DNA solution was incubated at 37°C for 2 hours. After treatment with phenol/chloroform, water layer was recovered and the DNA was ethanol precipitated, followed by centrifugation. The pellet was resuspended in 50 µl of TE buffer. Concentration of thus obtained genomic DNA was 88 ng/µl.

Example 3: Cloning of partial enone reductase gene of *C. kefir* (*C. macedoniensis*) IFO 0960

Using the prepared genomic DNA as a template, a partial sequence for the enone reductase gene was obtained by degenerate PCR amplification using a thermal cycler (Perkin-Elmer Cetus Instruments, USA). The degenerate PCR primers were designed based on the partial amino acid sequences (K-15, K-13.1, and K-9) obtained in Example 1, and were as follows:

Sense 1 (SEQ ID NO: 19)

GlyAspThrAsnIlePheLysProIle
5'-GGIGATAACIAATATATTTAAACCAAT-3'
15 C C T C G T
C G
C

Anti 2 (SEQ ID NO: 20)

GlyGluLysThrPheThrTyrPheThr
20 5'-CCTTCTTTAGTAAAGTATAAAAGT-3'
C C T G G G
G
G

The PCR reaction (50 µl) was carried out using 176 ng of chromosomal DNA (obtained in Example 2) as a template, 150 pmol each of degenerate primer, 2.5 nmol each of dATP, dCTP, dGTP, and dTTP, 1.5 units of Ex Taq polymerase (Takara Shuzo, Kyoto, Japan), and 5 µl of EX Taq buffer (Takara Shuzo). The initial template denaturation step consisted of 4 min at 94°C. An amplification cycle of 1 min at 94°C, 1 min at 50°C, and 1.5 min at 72°C was repeated for 35 times. After additional 10 min reaction at 72°C, a DNA fragment containing a partial enone reductase gene (approx. 1 kb) was amplified. This fragment was cloned on a sequencing vector, and DNA sequence was determined by the dideoxy chain-termination method. A Taq dye primer sequencing kit was used with an autosequencer (DNA Sequencer 373A, Applied Biosystems). The partial DNA sequence

thus obtained for the enone reductase and deduced amino acid sequence are as illustrated in SEQ ID NO:21 and SEQ ID NO:22, respectively.

Example 4: Cloning of complete enone reductase gene of *C. kefyr* (*C. macedoniensis*) IFO 0960

- 5 The inverse PCR was used to clone both upstream and downstream sequence flanking the partial enone reductase DNA sequence obtained in Example 3.
- 1 μ g of the genomic DNA of *C. kefyr* (*C. macedoniensis*) IFO 0960 (obtained in Example 2) was digested with 10 units of Nco I (Takara Shuzo, Kyoto, Japan) in 50 μ l of K-buffer containing 0.01 % BSA. After overnight reaction at 37°C, the reaction mixture was treated
- 10 with phenol/chloroform, the water layer was recovered and the DNA was ethanol precipitated, followed by centrifugation. The DNA pellet was resuspended in 1 ml of T4 DNA ligase buffer containing 700 units of T4 DNA ligase (Takara Shuzo). After overnight reaction at 15°C, the reaction mixture was treated with phenol/chloroform, the water layer was recovered and the DNA was ethanol precipitated, followed by centrifugation. The DNA
- 15 pellet was resuspended in TE buffer and used as a template for PCR. The PCR primers were designed based on the partial enone reductase gene sequence obtained in Example 3, and were as follows: IA1 (antisense primer for upstream region) = SEQ ID NO:23 and IS1 (sense primer for downstream region) = SEQ ID NO: 24.
- The PCR reaction (50 μ l) was carried out using 250 ng of the template DNA, 5 pmol each
- 20 of primer, 2.5 nmol each of dATP, dCTP, dGTP, and dTTP, 2.5 units of Ex Taq polymerase (Takara Shuzo), and 5 μ l of EX Taq buffer (Takara Shuzo). The initial template denaturation step consisted of 4 min at 94°C. An amplification cycle of 1 min at 94°C, 1 min at 60°C, and 4 min at 72°C was repeated for 30 times. After additional 10 min reaction at 72°C, a DNA fragment (approx. 4 kb) containing the upstream and downstream sequence
- 25 of the enone reductase gene was amplified. This fragment was cloned on a sequencing vector, and DNA sequence was determined.
- By combining the thus obtained sequence with the partial enone reductase DNA sequence obtained in Example 3, an estimated entire gene sequence containing its coding region as well as its regulatory region such as a promoter or a terminator was obtained. The
- 30 estimated entire DNA sequence thus obtained for the enone reductase is illustrated in SEQ ID NO: 25 containing the coding region as well as its flanking upstream and downstream region (estimated ORF is 148-1359).

Next, the actual entire sequence of the enone reductase gene containing its coding region as well as its flanking upstream and downstream region was obtained by PCR as follows.

The genomic DNA of *C. kefir* (*C. macedoniensis*) IFO 0960 (obtained in Example 2) was used as a template. The PCR primers were designed based on the estimated enone reductase gene sequence obtained above (SEQ ID NO: 25), and are illustrated in SEQ ID NO: 26 (Sense) and SEQ ID NO: 27 (Antisense).

- 5 The PCR reaction (50 μ l) was carried out using 900 ng of the template DNA, 10 pmol each of primer, 2.5 nmol each of dATP, dCTP, dGTP, and dTTP, 100 nmol of $MgCl_2$, 1.5 units of LA Taq polymerase (Takara Shuzo), and 5 μ l of LA Taq buffer (Takara Shuzo). The initial template denaturation step consisted of 2 min at 94°C. An amplification cycle of 1 min at 94°C, 1 min at 60°C, and 1.5 min at 74°C was repeated for 23 times. After additional 7 min reaction at 74°C, a DNA fragment (approx. 1.3 kb) containing the entire sequence of the enone reductase gene was amplified. This fragment was cloned on a sequencing vector, and the DNA sequence was determined.
- 10 The entire DNA sequence thus obtained for the enone reductase containing its coding region as well as its flanking upstream and downstream region is illustrated in SEQ ID NO:28 (ORF is 55-1266).
- 15

Example 5: Expression of the enone reductase gene and levodione production using *E.coli* having the enone reductase gene of *C. kefir*

- A DNA fragment containing just the ORF of the enone reductase gene (1212 bp) was obtained by PCR amplification. The PCR was performed with primers, ExS (SEQ ID NO:29) and ExA (SEQ ID NO:30).
- 20

- The vector carrying the entire sequence of the enone reductase gene (obtained in Example 4) was used as a template. The PCR reaction (50 μ l) was carried out using 250 ng of the template DNA, 10 pmol each of primer, 2.5 nmol each of dATP, dCTP, dGTP, and dTTP, 1.5 units of Pyrobest DNA polymerase (Takara Shuzo), and 5 μ l of Pyrobest buffer (Takara Shuzo). The initial template denaturation step consisted of 1 min at 94°C. An amplification cycle of 0.5 min at 94°C, 1 min at 60°C, and 1.5 min at 75°C was repeated for 15 times. After additional 5 min reaction at 75°C, a DNA fragment (approx. 1.2 kb) containing just the ORF of enone reductase gene was amplified.
- 25

- This amplified fragment of the enone reductase gene was cloned on a vector, pET101/D-TOPO, using a pET Directional TOPO® Expression Kits (Invitrogen Corporation, USA) according to an instruction manual prepared by the manufacturer. The vector carrying the enone reductase gene thus obtained (pET101/D-TOPO-ER) was introduced into *E.coli* BL21 (DE3), and several clones were selected for sequence analysis using an automatic sequence analyzer (DNA Sequencer 373A, Applied Biosystems). One of the clones, *E.coli*
- 30

BL21 (DE3)[pET101/D-TOPO-ER], that showed completely the same sequence as the enone reductase sequence of *C. kefir* was selected for further experiments. The strain, *E.coli* BL21 (DE3)[pET101/D-TOPO] was also prepared as a control.

Each of the strains, *E.coli* BL21 (DE3)[pET101/D-TOPO-ER] and *E.coli* BL21

- 5 (DE3)[pET101/D-TOPO], was inoculated into the M9 minimum medium (5 ml in tube) containing 0.05 mg/ml of ampicillin and 2 % (W/V) of casamino acids (Difco laboratories, USA) and cultivated at 37°C. When the optical density at 610 nm reached 0.4, IPTG (isopropyl beta-D-thiogalactopyranoside) was added to the medium to make the concentration 0.01 mM and cultivation was continued for further 8-10 hours. Then the cells were
10 collected by centrifugation, and a portion of the cells was used for SDS-PAGE analysis. As a result, an IPTG-induced protein band estimated as 45 kDa was observed only when the recombinant strain, *E.coli* BL21 (DE3)[pET101/D-TOPO-ER] was used.

- The rest of the collected cells was resuspended into 2 ml of 100 mM potassium phosphate buffer (pH 7.0). The suspension was used for confirming an activity to produce levodione
15 from ketoisophorone. This suspension was divided into two portions (1 ml each), and the reaction was started by adding 33 mM (final concentration, hereinafter abbreviated as f.c.) of ketoisophorone and 280 mM (f.c.) of D-glucose with or without 0.37 mM (f.c.) of NAD⁺, 15 units / ml (f.c.) of glucose dehydrogenase. The reaction was carried out at 30°C overnight. The reaction mixture was extracted with ethylacetate to recover levodione in
20 the ethylacetate layer. The extract was analyzed by gas chromatography. As a result, levodione was detected only when the recombinant strain, *E.coli* BL21 (DE3)[pET101/D-TOPO-ER] was used.

SEQUENCE LISTING

<110> Roche Vitamins AG
 <120> Enone reductase gene
 <130> NDR5231
 5 <160> 30
 <170> PatentIn version 3.1

<210> 1
 10 <211> 1212
 <212> DNA
 <213> Candida kefyr
 <220>
 <221> CDS
 15 <222> (1)..(1212)
 <223>
 <400> 1
 atg tcg tac atg aac ttt gac cct aag cca ttg gga gac acc aat atc 48
 Met Ser Tyr Met Asn Phe Asp Pro Lys Pro Leu Gly Asp Thr Asn Ile
 20 1 5 10 15
 ttc aag cca atc aag atc ggt aac aat gag cta aaa cac aga gta gtc 96
 Phe Lys Pro Ile Lys Ile Gly Asn Asn Glu Leu Lys His Arg Val Val
 20 25 30
 25 atg cca gca ttg act aga atg aga gcc att gca cca gga aac atc cca 144
 Met Pro Ala Leu Thr Arg Met Arg Ala Ile Ala Pro Gly Asn Ile Pro
 35 40 45
 30 aac act gaa tgg gcc gag gaa tac tac aga caa cgt tct caa tac cct 192
 Asn Thr Glu Trp Ala Glu Glu Tyr Tyr Arg Gln Arg Ser Gln Tyr Pro
 50 55 60
 ggt acc ctt att atc acg gaa ggt act ttc cct tct gcg caa tca ggt 240
 35 Gly Thr Leu Ile Ile Thr Glu Gly Thr Phe Pro Ser Ala Gln Ser Gly
 65 70 75 80
 ggt tac cca aat gtg cca ggt atc tgg tcc aaa gag caa ttg gct gaa 288
 Gly Tyr Pro Asn Val Pro Gly Ile Trp Ser Lys Glu Gln Leu Ala Glu
 40 85 90 95

	tgg aaa aag atc ttc aat gca atc cat gag aac aaa tcg ttc gtg tgg	336
	Trp Lys Lys Ile Phe Asn Ala Ile His Glu Asn Lys Ser Phe Val Trp	
	100 105 110	
5	gtg caa ttg tgg gtt cta ggt aga caa gca tgg cca gaa gtg ttg aag	384
	Val Gln Leu Trp Val Leu Gly Arg Gln Ala Trp Pro Glu Val Leu Lys	
	115 120 125	
	aag gaa ggt ttg cgt tac gat agt gct acc gat gac ttg tac atg ggt	432
10	Lys Glu Gly Leu Arg Tyr Asp Ser Ala Thr Asp Asp Leu Tyr Met Gly	
	130 135 140	
	gaa gaa gaa aaa gag cgt gcc tta aag gct aac aac cca cag cac ggt	480
	Glu Glu Glu Lys Glu Arg Ala Leu Lys Ala Asn Asn Pro Gln His Gly	
15	145 150 155 160	
	atc acc aag gaa gaa atc aag cag tac atc aag gag tac gtg gat gct	528
	Ile Thr Lys Glu Glu Ile Lys Gln Tyr Ile Lys Glu Tyr Val Asp Ala	
	165 170 175	
20	gcc aag aaa gcc atc gat gca ggt gca gac ggt gtg caa atc cat tct	576
	Ala Lys Lys Ala Ile Asp Ala Gly Ala Asp Gly Val Gln Ile His Ser	
	180 185 190	
25	gcc aac ggt tac ttg ttg aac cag ttt ttg gac cct att tct aac aac	624
	Ala Asn Gly Tyr Leu Leu Asn Gln Phe Leu Asp Pro Ile Ser Asn Asn	
	195 200 205	
	aga acc gac gag tac ggt gga tcg atc gag aac cgt gcg aga ttc act	672
30	Arg Thr Asp Glu Tyr Gly Gly Ser Ile Glu Asn Arg Ala Arg Phe Thr	
	210 215 220	
	ttg gaa gtg gtc gat gcc gtt gtc gat gca gtt ggt gcc gaa aga acc	720
	Leu Glu Val Val Asp Ala Val Val Asp Ala Val Gly Ala Glu Arg Thr	
35	225 230 235 240	
	tcc atc aga ttc tct cca tac ggt act ttt ggt acc atg tcc ggt ggt	768
	Ser Ile Arg Phe Ser Pro Tyr Gly Thr Phe Gly Thr Met Ser Gly Gly	
	245 250 255	
40	gag aac cct ggc atc gct gct caa tat gca tac gtc att ggt gag ttg	816
	Glu Asn Pro Gly Ile Val Ala Gln Tyr Ala Tyr Val Ile Gly Glu Leu	
	260 265 270	
	gaa aag aga gct aga gct ggc aag aga ttg gcg ttc atc gat ttg gtc	864

<400> 2
Met Ser Tyr Met Asn Phe Asp Pro Lys Pro Leu Gly Asp Thr Asn Ile
1 5 10 15
5 Phe Lys Pro Ile Lys Ile Gly Asn Asn Glu Leu Lys His Arg Val Val
20 25 30
Met Pro Ala Leu Thr Arg Met Arg Ala Ile Ala Pro Gly Asn Ile Pro
35 40 45
10 Asn Thr Glu Trp Ala Glu Glu Tyr Tyr Arg Gln Arg Ser Gln Tyr Pro
50 55 60
Gly Thr Leu Ile Ile Thr Glu Gly Thr Phe Pro Ser Ala Gln Ser Gly
15 65 70 75 80
Gly Tyr Pro Asn Val Pro Gly Ile Trp Ser Lys Glu Gln Leu Ala Glu
85 90 95
20 Trp Lys Lys Ile Phe Asn Ala Ile His Glu Asn Lys Ser Phe Val Trp
100 105 110
Val Gln Leu Trp Val Leu Gly Arg Gln Ala Trp Pro Glu Val Leu Lys
115 120 125
25 Lys Glu Gly Leu Arg Tyr Asp Ser Ala Thr Asp Asp Leu Tyr Met Gly
130 135 140
Glu Glu Glu Lys Glu Arg Ala Leu Lys Ala Asn Asn Pro Gln His Gly
30 145 150 155 160
Ile Thr Lys Glu Glu Ile Lys Gln Tyr Ile Lys Glu Tyr Val Asp Ala
165 170 175
35 Ala Lys Lys Ala Ile Asp Ala Gly Ala Asp Gly Val Gln Ile His Ser
180 185 190
Ala Asn Gly Tyr Leu Leu Asn Gln Phe Leu Asp Pro Ile Ser Asn Asn
195 200 205
40 Arg Thr Asp Glu Tyr Gly Gly Ser Ile Glu Asn Arg Ala Arg Phe Thr
210 215 220
Leu Glu Val Val Asp Ala Val Val Asp Ala Val Gly Ala Glu Arg Thr

	225		230		235		240
	Ser Ile Arg Phe	Ser Pro Tyr Gly Thr	Phe Gly Thr Met	Ser Gly Gly			
		245	250	255			
5	Glu Asn Pro Gly	Ile Val Ala Gln Tyr	Ala Tyr Val Ile	Gly Glu Leu			
		260	265	270			
	Glu Lys Arg Ala	Arg Ala Gly Lys Arg	Leu Ala Phe Ile	Asp Leu Val			
10		275	280	285			
	Glu Pro Arg Val	Thr Asp Pro Phe	Leu Pro Glu Phe	Glu Lys Trp Phe			
		290	295	300			
15	Lys Glu Gly Thr	Asn Glu Phe Ile	Tyr Ser Ile Trp	Lys Gly Pro Val			
	305	310	315	320			
	Leu Arg Val Gly	Asn Tyr Ala Leu	Asp Pro Asp Gln	Ala Thr Leu Asp			
		325	330	335			
20	Ser Lys Lys Pro	Asn Thr Leu Ile	Gly Tyr Gly Arg	Ser Phe Ile Ala			
		340	345	350			
	Asn Pro Asp Leu	Val Tyr Arg Leu	Glu Lys Gly Leu	Pro Leu Asn Lys			
25		355	360	365			
	Tyr Asp Arg Asn	Thr Phe Tyr Thr	Phe Thr Lys Glu	Gly Tyr Thr Asp			
		370	375	380			
30	Tyr Pro Ser Tyr	Glu Glu Ser Val	Ala Lys Gly Tyr	Lys Lys Glu Glu			
	385	390	395	400			
	Lys Lys Tyr						
35							
	<210>	3					
	<211>	12					
	<212>	PRT					
40	<213>	Candida kefyr					
	<400>	3					
	Pro Leu Gly Asp	Thr Asn Ile Phe	Lys Pro Ile Lys				

1 5 10

<210> 4
5 <211> 50
<212> PRT
<213> Candida kefyr

<400> 4
10 His Arg Val Val Met Pro Ala Leu Thr Arg Met Arg Ala Ile Ala Pro
1 5 10 15

Gly Asn Ile Pro Asn Thr Glu Trp Ala Glu Glu Tyr Tyr Arg Gln Arg
20 25 30
15 Ser Gln Tyr Pro Gly Thr Leu Ile Ile Thr Glu Gly Thr Phe Pro Ser
35 40 45

Val Gln
20 50

<210> 5
<211> 8
25 <212> PRT
<213> Candida kefyr

<400> 5
Glu Gln Leu Ala Glu Trp Lys Lys
30 1 5

<210> 6
<211> 9
35 <212> PRT
<213> Candida kefyr

<400> 6
Ile Phe Asn Ala Ile His Glu Asn Lys
40 1 5

<210> 7
<211> 18
<212> PRT

<213> Candida kefyr
<220>
<221> MISC_FEATURE
<222> (15)..(15)
5 <223>
<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> Xaa is unknown
10
<400> 7
Ser Phe Val Trp Val Gln Leu Trp Val Leu Gly Arg Gln Ala Xaa Pro
1 5 10 15
15 Glu Val

<210> 8
20 <211> 19
<212> PRT
<213> Candida kefyr

<400> 8
25 Glu Gly Leu Arg Tyr Asp Ser Ala Phe Asp Asp Leu Tyr Met Gly Glu
1 5 10 15
Glu Glu Lys
30

<210> 9
<211> 10
<212> PRT
35 <213> Candida kefyr

<400> 9
Ala Asn Asn Pro Gln His Gly Ile Thr Lys
1 5 10
40
<210> 10
<211> 7
<212> PRT

<213> Candida kefyr

<400> 10

Glu Tyr Val Asp Ala Ala Lys

5 1 5

<210> 11

<211> 50

10 <212> PRT

<213> Candida kefyr

<220>

<221> MISC_FEATURE

<222> (43)..(43)

15 <223> Xaa is unknown

<220>

<221> MISC_FEATURE

<222> (47)..(48)

<223> Xaa is unknown

20 <220>

<221> MISC_FEATURE

<222> (45)..(45)

<223> Xaa is unknown

25 <400> 11

Ala Ile Asp Ala Gly Ala Asp Gly Val Gln Ile His Ser Ala Asn Gly

1 5 10 15

30 Tyr Leu Leu Asn Gln Phe Leu Asp Pro Ile Ser Asn Asn Arg Thr Asp

20 25 30

Glu Tyr Gly Gly Ser Ile Ile Asn Arg Ala Xaa Phe Xaa Leu Xaa Xaa

35 40 45

35

Val Asp

50

40 <210> 12

<211> 22

<212> PRT

<213> Candida kefyr

<400> 12

Arg Leu Ala Phe Ile Asp Leu Val Glu Pro Arg Val Thr Asp Pro Phe
1 5 10 15

5 Leu Pro Glu Phe Glu Lys
20

<210> 13

10 <211> 12

<212> PRT

<213> Candida kefyr

<400> 13

15 Glu Gly Thr Asn Glu Phe Ile Tyr Ser Ile Trp Lys
1 5 10

<210> 14

20 <211> 21

<212> PRT

<213> Candida kefyr

<400> 14

25 Gly Pro Val Leu Arg Val Gly Asn Tyr Ala Leu Asp Pro Asp Gln Ala
1 5 10 15

Thr Leu Asp Ser Lys

30 20

<210> 15

<211> 24

35 <212> PRT

<213> Candida kefyr

<400> 15

40 Leu Pro Asn Thr Leu Ile Gly Tyr Gly Arg Ser Phe Ile Ala Asn Pro
1 5 10 15

Asp Leu Val Tyr Arg Leu Glu Lys

20

<210> 16
5 <211> 6
<212> PRT
<213> Candida kefyr

<400> 16
10 Gly Leu Pro Leu Asn Lys
1 5

<210> 17
15 <211> 11
<212> PRT
<213> Candida kefyr

<400> 17
20 Tyr Asp Arg Asn Thr Phe Tyr Thr Phe Thr Lys
1 5 10

<210> 18
25 <211> 15
<212> PRT
<213> Candida kefyr

<400> 18
30 Glu Gly Tyr Thr Asp Tyr Pro Ser Tyr Glu Glu Ser Val Ala Lys
1 5 10 15

<210> 19
35 <211> 9
<212> PRT
<213> Artificial

<400> 19
40 Gly Asp Thr Asn Ile Phe Lys Pro Ile
1 5

<210> 20
 <211> 9
 <212> PRT
 <213> Artificial

5
 <400> 20
 Gly Glu Lys Thr Phe Thr Tyr Phe Thr
 1 5

10
 <210> 21
 <211> 1058
 <212> DNA
 <213> Candida kefyr

15
 <220>
 <221> CDS
 <222> (1)..(1056)
 <223>

20
 <400> 21
 cac aga gta gtc atg cca gca ttg act aga atg aga gcc att gca cca 48
 His Arg Val Val Met Pro Ala Leu Thr Arg Met Arg Ala Ile Ala Pro
 1 5 10 15

25
 gga aac atc cca aac act gaa tgg gcc gag gaa tac tac aga caa cgt 96
 Gly Asn Ile Pro Asn Thr Glu Trp Ala Glu Glu Tyr Tyr Arg Gln Arg
 20 25 30

30
 tct caa tac cct ggt acc ctt att atc acg gaa ggt act ttc cct tct 144
 Ser Gln Tyr Pro Gly Thr Leu Ile Ile Thr Glu Gly Thr Phe Pro Ser
 35 40 45

35
 gcg caa tca ggt ggt tac cca aat gtg cca ggt atc tgg tcc aaa gag 192
 Ala Gln Ser Gly Gly Tyr Pro Asn Val Pro Gly Ile Trp Ser Lys Glu
 50 55 60

40
 caa ttg gct gaa tgg aaa aag atc ttc aat gca atc cat gag aac aaa 240
 Gln Leu Ala Glu Trp Lys Lys Ile Phe Asn Ala Ile His Glu Asn Lys
 65 70 75 80

40
 tcg ttc gtg tgg gtg caa ttg tgg gtt cta ggt aga caa gca tgg cca 288
 Ser Phe Val Trp Val Gln Leu Trp Val Leu Gly Arg Gln Ala Trp Pro
 85 90 95

	gaa gtg ttg aag aag gaa ggt ttg cgt tac gat agt gct acc gat gac	336
	Glu Val Leu Lys Lys Glu Gly Leu Arg Tyr Asp Ser Ala Thr Asp Asp	
	100 105 110	
5	ttg tac atg ggt gaa gaa gaa aaa gag cgt gcc tta aag gct aac aac	384
	Leu Tyr Met Gly Glu Glu Glu Lys Glu Arg Ala Leu Lys Ala Asn Asn	
	115 120 125	
	cca cag cac ggt atc acc aag gaa gaa atc aag cag tac atc aag gag	432
10	Pro Gln His Gly Ile Thr Lys Glu Glu Ile Lys Gln Tyr Ile Lys Glu	
	130 135 140	
	tac gtg gat gct gcc aag aaa gcc atc gat gca ggt gca gac ggt gtg	480
	Tyr Val Asp Ala Ala Lys Lys Ala Ile Asp Ala Gly Ala Asp Gly Val	
15	145 150 155 160	
	caa atc cat tct gcc aac ggt tac ttg ttg aac cag ttt ttg gac cct	528
	Gln Ile His Ser Ala Asn Gly Tyr Leu Leu Asn Gln Phe Leu Asp Pro	
	165 170 175	
20	att tct aac aac aga acc gac gag tac ggt gga tct atc gag aac cgt	576
	Ile Ser Asn Asn Arg Thr Asp Glu Tyr Gly Gly Ser Ile Glu Asn Arg	
	180 185 190	
25	gcg aga ttc act ttg gaa gtg gtt gat gcc gtt gta gat gca gtt ggt	624
	Ala Arg Phe Thr Leu Glu Val Val Asp Ala Val Val Asp Ala Val Gly	
	195 200 205	
	gcc gaa aga acc tcc atc aga ttc tct cct tac ggt act ttt ggt acc	672
30	Ala Glu Arg Thr Ser Ile Arg Phe Ser Pro Tyr Gly Thr Phe Gly Thr	
	210 215 220	
	atg tcc ggt ggt gag aac cct gcc atc gtt gcc caa tat gca tac gtc	720
	Met Ser Gly Gly Glu Asn Pro Gly Ile Val Ala Gln Tyr Ala Tyr Val	
35	225 230 235 240	
	att ggt gag ttg gaa aag aga gct aga gct gcc aag aga ttg gcc ttc	768
	Ile Gly Glu Leu Glu Lys Arg Ala Arg Ala Gly Lys Arg Leu Ala Phe	
	245 250 255	
40	atc gat ttg gtc gag cct cgt gtg acc gac cca ttc cta cca gaa ttc	816
	Ile Asp Leu Val Glu Pro Arg Val Thr Asp Pro Phe Leu Pro Glu Phe	
	260 265 270	
	gag aag tgg ttc aag gaa ggt acc aac gaa ttc atc tac tct atc tgg	864

25

	85	90	95
	Glu Val Leu Lys Lys Glu Gly Leu Arg Tyr Asp Ser Ala Thr Asp Asp		
	100	105	110
5	Leu Tyr Met Gly Glu Glu Glu Lys Glu Arg Ala Leu Lys Ala Asn Asn		
	115	120	125
	Pro Gln His Gly Ile Thr Lys Glu Glu Ile Lys Gln Tyr Ile Lys Glu		
10	130	135	140
	Tyr Val Asp Ala Ala Lys Lys Ala Ile Asp Ala Gly Ala Asp Gly Val		
	145	150	155 160
15	Gln Ile His Ser Ala Asn Gly Tyr Leu Leu Asn Gln Phe Leu Asp Pro		
	165	170	175
	Ile Ser Asn Asn Arg Thr Asp Glu Tyr Gly Gly Ser Ile Glu Asn Arg		
	180	185	190
20	Ala Arg Phe Thr Leu Glu Val Val Asp Ala Val Val Asp Ala Val Gly		
	195	200	205
	Ala Glu Arg Thr Ser Ile Arg Phe Ser Pro Tyr Gly Thr Phe Gly Thr		
25	210	215	220
	Met Ser Gly Gly Glu Asn Pro Gly Ile Val Ala Gln Tyr Ala Tyr Val		
	225	230	235 240
30	Ile Gly Glu Leu Glu Lys Arg Ala Arg Ala Gly Lys Arg Leu Ala Phe		
	245	250	255
	Ile Asp Leu Val Glu Pro Arg Val Thr Asp Pro Phe Leu Pro Glu Phe		
35	260	265	270
	Glu Lys Trp Phe Lys Glu Gly Thr Asn Glu Phe Ile Tyr Ser Ile Trp		
	275	280	285
40	Lys Gly Pro Val Leu Arg Val Gly Asn Tyr Ala Leu Asp Pro Asp Gln		
	290	295	300
	Ala Thr Ile Asp Ser Lys Lys Pro Asn Thr Leu Ile Gly Tyr Gly Arg		
	305	310	315 320

Ser Phe Ile Ala Asn Pro Asp Leu Val Tyr Arg Leu Glu Lys Gly Leu
325 330 335

5 Pro Leu Asn Lys Tyr Asp Arg Asn Thr Phe Tyr Thr Phe Thr Lys Glu
340 345 350

<210> 23
10 <211> 25
<212> DNA
<213> Artificial

<400> 23
15 attctctcggc ccattcagtg ttggg 25

<210> 24
<211> 26
20 <212> DNA
<213> Artificial

<400> 24
25 ggtgtaccgc ttggaaaagg gtttgc 26

<210> 25
<211> 1796
<212> DNA
30 <213> Candida kefyr

<400> 25
35 tatatatata tatatgtata tatttaggtt aatactgagt atttgactta gaataaagaa 60
ggctaataatc ggtagtagta gtggtagcag ttagagcacc tgcagcaccg agacctaaact 120
aattaartat atcaacaaac tgcgcgagatg tgcgtacatga actttgaccc taagccattg 180
40 ggagacacca atatcttcaa gccaatcaag atcggtaaca atgagctaaa acacagagta 240
gtcatgccag cattgactag aatgagagcc attgcaccag gaaacatccc aaacactgaa 300
tgggdcgagg aatactacag acaacgttct caataccctg gtacccttat tatcacggaa 360

ggtactttcc cttctgcgca atcaggtggg tacccaaagtg tgccaggtat ctgggtccaaa 420
 gagcaattgg ctgaatggaa aaagatcttc aatgcaatcc atgagaacaa atcggttcgtg 480
 5 tgggtgcaat tgtgggttcc aggtagacaa gcatggccag aagtgttgaa gaaggaaggt 540
 ttgcgttacg atagtgtac cgatgacttg tacatgggtg aagaagaaaa agagcgtgcc 600
 10 ttaaaggcta acaaccacaa gcacgggtatc accaaggaag aaatcaagca gtacatcaag 660
 ggtacgtgg atgctgcaa gaaagccatc gatgcagggtg cagacgggtg gcaaatccat 720
 tctgccaacg gttacttgtt gaaccagttt ttggacccta tttctaacaa cagaaccgac 780
 15 ggtacgggtg gatcgatcga gaaccgtgcg agattcactt tgggaagtggg tgatgccgtt 840
 gtagatgcag ttgggtgcga aagaacctcc atcagattcc ctccctacgg tacttttggg 900
 20 accatgtccg gtgggtgagaa ccctggcacc gttgcccac atgcatacgt cattgggtgag 960
 ctggaaaaga gagctagagc tggcaagaga ttggccttca tggatttggg cgagccctcg 1020
 gtgaccgacc cattccctacc agaattcgag aagtgggttca aggaagggtac caacgaattc 1080
 25 atctactcta tctggaaggg tccagttctc agagttggta actatgcttt ggaccagat 1140
 caagctacta tgcactccta gaagcctaac accttgatcg gttacggtag atcctttatt 1200
 30 gccaaaccag acttgggtgta ccgtttggaa aagggtttgc cattgaacaa gtatgataga 1260
 aacaccttct acaccttcac caaagaaggt tacaccgatt acccaagcta cgaggaatcc 1320
 gtcgcaaagg gttacaagaa agaggaaaag aagtactaag cttgaactga taactragcca 1380
 35 ggaccagaat ctgtcatcct ctctacttct taattaattt ttatgtatga tggatgactt 1440
 taatattata ttattatata atacatatgc ctaaactaac tactacactt gggaaattgg 1500
 40 tggcagatga ggggcctttg accttcaatg tttgtatgta agtaatgatt caaaagattc 1560
 tcctctatag ttgggttagtt actactaaaa gaaaccttca atataaaaaca atgatcgaga 1620
 atacattatt aaattaacct atgaacttat azaataaaaag agataaaaata aaattaaaaa 1680

ctaccattaa gtctttgtgc gaaatgagta accttatatt aataaaagat gtgaagtgtg 1740

gtgtacgtgt gcgtgtacgt gcgtgtgcaa aatttgtgtg tgcctaagtg taaaaat 1796

5

<210> 26

<211> 20

<212> DNA

10 <213> Artificial

<400> 26

gagcatctgc agcaccgaga 20

15

<210> 27

<211> 20

<212> DNA

<213> Artificial

20

<400> 27

gagaggatga cagattctgg 20

25

<210> 28

<211> 1310

<212> DNA

<213> Candida kefyr

30

<400> 28

gagcatctgc agcaccgaga cctaactaat taattatatt aacaaactgt cgagatgtcg 60

tacatgaact ttgacctaa gccattggga gacaccaata tcttcaagcc aatcaagatc 120

35

ggtaacaatg agctaaaaca cagagtagtc atgccagcat tgactagaat gagagccatt 180

gcaccaggaa acatcccaaa cactgaatgg gccgaggaat actacagaca acgttctcaa 240

40

tacctggta ccttattat caccgaaggt acttccctt ctgcgcaatc aggtggttac 300

ccaaatgtgc caggtatctg gtccaaagag caatcggctg aatggaaaaa gatcttcaat 360

gcaatccatg agaacaaatc gtccgtgtgg gtgcaattgt gggttctagg tagacaagca 420

5 tggccagaag tggtgaagaa ggaaggtttg cgttacgata gtgctaccga tgacttctac 480
 atgggtgaag aagaaaaaga gcgtgcctta aaggctaaca acccacagca cggtatcacc 540
 aaggaagaaa tcaagcagta catcaaggag tacgtggatg ctgccaaagaa agccatcgat 600
 gcaggtgcag acgggtgtgca aatccattct gccaacgggt acttggtgaa ccagttcttg 660
 10 gacctatatt ctaacaacag aaccgacgag tacggtggat cgatcgagaa ccgtgcgaga 720
 ttcactttgg aagtggtcga tgccgtctgc gatgcagttg gtgccgaaag aacctccatc 780
 agattctctc catacggtac ttttgggtacc atgtccgggt gtgagaacct tggcatcggt 840
 15 gctcaatatg catacgtcat tgggtgagtc gaaaagagag cttagagctgg caagagattg 900
 gcgttcacgt atttgggtcga gcctcgtgtg accgacccat tctaccaga attcgagaag 960
 20 tggttcaagg aaggtaccaa cgaattcatt tactctatct ggaagggtcc agttctcaga 1020
 gttggtaact atgctttgga cccagatcaa gccactctcg actctaagaa gcctaacact 1080
 ttgatcggtc acggtagatc cttcatcgcc aaccagact tgggtgtaccg tttggaaaag 1140
 25 ggtctgccat tgaacaagta tgatagaaac accttttaca cattcactaa ggaagggtac 1200
 accgattacc caagctacga agaattccgt gccaaagggtt acaagaaaga ggaaaagaag 1260
 30 tactaagctt gaactgataa ctaggcagga ccagaattct tcatcctctc 1310

35 <210> 29
 <211> 25
 <212> DNA
 <213> Artificial

40 <400> 29
 caccatgtcg tacatgaact ttgac 25

<210> 30
 <211> 29
 <212> DNA

- 33 -

<213> Artificial

<400> 30

tragtacttc ttttctcttt tcttgtaac

29

5

Claims

1. An isolated DNA comprising a nucleotide sequence coding for an enzyme having enone reductase activity wherein the enzyme is characterized by the following physico-chemical properties:
 - 5 (a) molecular mass: $61,300 \pm 5,000$ Da
(estimated using gel filtration, consisting of one subunit);
 - (b) co-factor: NADPH and NADH;
 - (c) substrate specificity: active on α,β -unsaturated ketons;
 - (d) optimum temperature: $55-60^{\circ}\text{C}$ at pH 7.4; and
 - 10 (e) optimum pH: pH 4.5-8.5.
2. The isolated DNA according to claim 1, wherein said nucleotide sequence is selected from the group consisting of:
 - (a) a nucleotide sequence coding for a polypeptide having the amino acid sequence shown in SEQ ID NO:2;
 - 15 (b) a nucleotide sequence coding for an allelic variant of the polypeptide having the amino acid sequence shown in SEQ ID NO:2; and
 - (c) a nucleotide sequence coding for a polypeptide having the amino acid sequence shown in SEQ ID NO:2, in which one or more amino acids are added, inserted, deleted and/or substituted but having the enone reductase activity.
- 20 3. The isolated DNA according to claim 1, wherein said nucleotide sequence is selected from the group consisting of:
 - (a) a nucleotide sequence represented in SEQ ID NO:1;
 - (b) a nucleotide sequence encoding an enone reductase having the amino acid sequence encoded by the nucleotide sequence shown in SEQ ID NO:1;
 - 25 (c) a nucleotide sequence which hybridizes to the complement of the nucleotide sequence of (a) or (b) under stringent hybridizing conditions; and
 - (d) a nucleotide sequence which is at least 80% identical to the nucleotide sequence of (a).
4. A vector or a plasmid comprising the DNA of claim 1.
5. A host cell transformed or transfected by the DNA of claim 1 or the vector or the
30 plasmid of claim 4.
6. A polypeptide encoded by the DNA of claim 1.

7. A process for the production of levodione, which comprises contacting ketoisophorone with the polypeptide of claim 6 under conditions suitable for the production of levodione, e.g. at pH values of from 4.5 to 8.5 and at a temperature range from 10 to 60 °C for 5 minutes to 72 hours, or at pH values of from 5.0 to 8.0 and at a temperature range from 20 to 60 °C for 15 minutes to 48 hours.

8. A process for the production of levodione, which comprises contacting ketoisophorone with the host cell of claim 5 or a cell-free extract thereof under the conditions suitable for the production of levodione, e.g. at pH values of from 4.0 to 9.0 and at a temperature range from 10 to 60 °C for 15 minutes to 72 hours, or at pH values of from 5.0 to 8.0 and at a temperature range from 20 to 60 °C for 30 minutes to 48 hours.

PCT Application
EP0310473



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.